Dr. Ribas on Anti-PD-1 Agent Lambrolizumab in Melanoma

Antoni Ribas, MD, PhD
Published Online: Monday, June 3, 2013


Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

Clinically meaningful activity was observed in a substantial number of patients in the trial, Ribas explains. The overall response rate by RECIST criteria was 38% with 90% of patients experiencing durable responses. At the highest dose, response was 52%. Most of the adverse events with lambrolizumab were minimal, Ribas suggests.

<<< View more from the 2013 ASCO Annual Meeting

Online CME Activities
Free CME from PER
Angiogenesis Inhibitors for Gastrointestinal Cancers: Update From the 2015 Gastrointestinal Cancers Symposium
Cancer Summaries and Commentaries™: Updates from San Francisco in Acute Myeloid Leukemia
Community Practice Connections: 9th Annual New York Lung Cancer Symposium®
Recap of SABCS 2014: Changes for Today and Hope for Tomorrow
More Reading
$auto_registration$